ANDA 212001, held by Custopharm Inc. Ganciclovir Sodium.
As of Nov 16, 2026, ANDA 212001 (Ganciclovir Sodium), held by Custopharm Inc, was first approved by FDA on Jun 20, 2019, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 20, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ganciclovir SodiumEQ 500MG BASE/VIAL ยท injectable;injection | Ganciclovir Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters